First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50)

Article Medicine, General & Internal

Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma

Y. Doki et al.

Summary: In patients with advanced esophageal squamous-cell carcinoma, both first-line treatment with nivolumab plus chemotherapy and first-line treatment with nivolumab plus ipilimumab resulted in significantly longer overall survival than chemotherapy alone, with no new safety signals identified.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Second-line pembrolizumab versus chemotherapy in Japanese patients with advanced esophageal cancer: subgroup analysis from KEYNOTE-181

Kei Muro et al.

Summary: The study focused on Japanese patients with advanced esophageal cancer, comparing the efficacy and safety of pembrolizumab and chemotherapy as second-line therapy. The results showed that pembrolizumab had a survival benefit and lower rates of treatment-related adverse events compared to chemotherapy in this patient population.

ESOPHAGUS (2022)

添加到收藏夹

Review Oncology

Association of Smoking Status with Efficacy of First-line Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancers: A Systematic Review and Meta-analysis

Jinchul Kim et al.

Summary: This meta-analysis investigates the impact of smoking status on the efficacy of first-line immunotherapy for advanced non-small cell lung cancer (NSCLC). The study finds that smoking status has a significant effect on treatment outcomes, with both checkpoint inhibitor monotherapy and checkpoint inhibitor plus chemotherapy showing a survival benefit in current/former smokers. However, there is inconsistent survival outcome in never-smokers, with checkpoint blockade monotherapy not showing significantly better efficacy than chemotherapy alone, but combination treatment showing an overall survival benefit.

JOURNAL OF CANCER (2022)

添加到收藏夹

Article Oncology

Toripalimab plus chemotherapy in treatment-naive, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial

Zi-Xian Wang et al.

Summary: This study found that toripalimab combined with paclitaxel and cisplatin can significantly improve progression-free survival and overall survival in patients with treatment-naive advanced esophageal squamous cell carcinoma, with manageable safety.

CANCER CELL (2022)

添加到收藏夹

Meeting Abstract Oncology

Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: First results of the phase III ORIENT-15 study

L. Shen et al.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study

Jong-Mu Sun et al.

Summary: This study aimed to evaluate the antitumor activity of pembrolizumab plus chemotherapy versus chemotherapy alone as first-line treatment in advanced esophageal cancer. Results showed that pembrolizumab plus chemotherapy significantly improved overall survival and progression-free survival in patients with esophageal squamous cell carcinoma.

LANCET (2021)

添加到收藏夹

Review Oncology